Commitments and Contingencies - Additional Information (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|---|
Mar. 31, 2024 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Loss Contingencies [Line Items] | ||||||
| Prepaid expenses and other current assets | $ 10,381,000 | $ 10,381,000 | $ 7,917,000 | |||
| Research and development expense | $ 51,414,000 | $ 22,680,000 | 84,130,000 | $ 42,252,000 | ||
| NeuroPace SOW | ||||||
| Loss Contingencies [Line Items] | ||||||
| Cumulative expense | $ 4,700,000 | |||||
| Period cost covered | 4 years | |||||
| NeuroPace SOW | Maximum | ||||||
| Loss Contingencies [Line Items] | ||||||
| Payment for service provided | $ 5,800,000 | |||||
| X | ||||||||||
- Definition Cumulative Expense No definition available.
|
| X | ||||||||||
- Definition Payment for service provided. No definition available.
|
| X | ||||||||||
- Definition Period over which cost incurred for the agreement. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|